KRAS Mutation Detection Kit
KRAS protein is a GTPase and one of the key molecules in the downstream signaling pathway of epidermal growth factor receptor (EGFR). KRAS protein transduces signals from membrane-bound receptors via multiple downstream effector pathways and thereby affects fundamental cellular processes, including proliferation, apoptosis, and differentiation. In total, activating mutations in the KRAS genes occur in 15~30% of lung cancer and 20~50% of colorectal cancer, mainly in exons 2, 3 or 4. The mutation status of the KRAS gene is relevant to the primary drug resistance of colorectal cancers treated with anti-EGFR monoclonal antibodies. Patients with wild-type KRAS gene could benefit from Erbitux (Cetuximab) or Vectibix (Panitumumab), whereas the patients with mutant KRAS gene show poor response to this treatment. The European Drug Administration Organization and US FDA approve the employment of KRAS gene mutation detection prior to the use of targeted medicines in the treatment of metastatic colorectal cancer.